Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions

Effects of other drugs on Palazestrant

9 evidence topics · 6 sources

Dose-normalized palazestrant trough concentrations with and without ribociclib
StudyDose-normalized steady-state trough, geometric mean (geometric SD); n90% confidence interval
OP-1250-001, single agent“2.49 (48%); 172”“[2.35, 2.64]”
OP-1250-003, combination with ribociclib“3.35 (61%); 25”“[2.77, 4.06]”